Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Canadian investors should consider some exposure to the industry for portfolio diversification, experts say.

Graham Hughes/The Canadian Press

U.S. health-care stocks took a beating last year amid worries about drug-price controls but have rallied since Donald Trump was elected president.

While some stocks may no longer be bargains, the sector is still compelling for investors because it can offer steady growth, potential benefits from proposed tax reform and stability during market turbulence, financial experts say.

The rally since November reflects enthusiasm that the industry could gain traction from lighter regulation and lower corporate taxes under a Trump presidency, suggests Christopher Davis (below), director of research at Morningstar Canada.

Story continues below advertisement

Christopher Davis, director of research at Morningstar Canada. The Globe and Mail J.P. MOCZULSKI The Globe and Mail

(J.P. Moczulski/The Globe and Mail)

The market was pretty much expecting Democratic candidate Hillary Clinton to win, and "have a heavier hand when it came to drug regulation," he says. "Even a tweet from her [to tackle 'price gouging'] would send drug stocks reeling."

The political uncertainty hanging over health-care policy has been lifted – at least for now – after Mr. Trump failed recently to repeal and replace the Affordable Care Act. Revoking this law, better known as Obamacare, would have raised the number of uninsured Americans and hurt the individual insurance market.

Despite recent turmoil in the sector, Canadian investors should still consider some exposure to the industry – if they don't have it – for portfolio diversification because health care is a tiny part of the domestic stock market, Mr. Davis says.

The industry tends to be an area of steady growth, and will benefit from an aging population needing medical care, he says. "In China and India, you have an increasing wealthy population and that is always good for health-care spending."

Exchange-traded funds (ETFs) focused on health care allow investors to cast a wider net and avoid the risk of owning a single stock, he says. The industry includes drug makers, hospitals, insurers, medical device makers and biotechnology firms.

Story continues below advertisement

U.S.-listed Vanguard Health Care ETF, which tracks 358 U.S. stocks and charges a 0.10-per-cent fee, is "probably our favourite," Mr. Davis says. Keep in mind that 10 stocks, which include names such as Johnson & Johnson, Pfizer Inc., and Merck & Co. Inc., make up 45 per cent of the portfolio, he notes.

He also likes Canadian-listed BMO Equal Weight U.S. Health Care Hedged to CAD ETF. With 52 stocks having equal weight, there is less concentration in individual names, while its currency is hedged to mitigate any impact, he says. "But it is more expensive with a 0.39-per-cent expense ratio."

National Bank Financial ETF analyst Daniel Straus (below) says that health care is also attractive as a defensive play because its stocks do well in an economic downturn. There is always consumer demand for medical products or services, he says.

National Bank Financial ETF analyst Daniel Straus. The Globe and Mail Kevin Van Paassen The Globe and Mail

(Kevin Van Paassen/The Globe and Mail)

While these stocks have been less volatile than the broader market over most of the past decade, political wrangling over the past year and a half has shaken some of the defensive underpinnings over the shorter term, he acknowledges.

Story continues below advertisement

With baby boomers aging and more efficiencies – and potential higher profits – arising from the adoption of technology, "it is a sector that does make sense as a long-term investment," Mr. Straus says. Many hospitals and health-care providers, for instance, still use paper versus electronic health records, he notes.

Some health-care firms, such as drug giants Eli Lilly and Co. and Bristol-Myers Squibb Co., could also benefit from Mr. Trump's pledge to cut corporate taxes, and provide a tax holiday for U.S. companies with huge cash stockpiles overseas. The president could provide more details on tax reform today. Cash repatriation would mean an inflow of capital that could be reinvested for growth, research and development, or expansion, he says.

As well, the recent passage of the 21st Century Cures Act, which provides for speedier approval for new drugs and devices by the U.S. Food and Drug Administration, could improve profitability at health-care firms, he adds.

Both Vanguard Health Care ETF as well as U.S.-listed Fidelity MSCI Health Care ETF, which tracks 344 U.S. stocks and charges a 0.08-per-cent fee, are cheaper ways to play the sector, he says. Fees matter because they eat away at returns.

For a pure play on drug companies, he likes U.S.-listed SPDR S&P Pharmaceuticals ETF, which charges a 0.35-per-cent fee, and iShares U.S. Pharmaceuticals ETF, with a 0.44-per-cent fee. There is obviously more risk in this bet, but also potentially a higher reward should this sub-sector outperform, he adds.

The health-care sector also holds appeal for income-seeking investors because many of its stocks offer steady and stable dividends, says Todd Rosenbluth, director of ETF and mutual fund research at New York-based CFRA Research.

Story continues below advertisement

Given that CFRA's stock analysts still find large-cap health-care companies to be attractively valued, U.S.-listed Health Care Select Sector SPDR ETF is a good way to get exposure to this part of the sector, Mr. Rosenbluth says. The fund, which has 60 holdings, charges a 0.14-per-cent fee.

Biotechnology firms, which invest millions to develop new health-care products, are likely to show continued growth, he adds. He favours U.S.-listed iShares Nasdaq Biotechnology ETF, which invests in larger-cap biotech firms. The fund tracks 162 stocks, which include names such as Celgene Corp., Gilead Sciences Inc., and Biogen Inc. The fund charges a 0.47-per-cent fee.

Because there could be more volatility in the U.S. market in the near term, Mr. Rosenbluth prefers ETFs holding larger-company names.

"We are eight years into a bull market, and are heading into a time period seasonally when markets start to get choppy," he says, referring to the investment axiom "sell in May, and go away."

"There is also a lot of uncertainty about … whether the Affordable Care Act stays in place, or gets replaced by something else," he says. "The act added people to the health-care system, which drove demand for pharmaceuticals, biotechnology products, medical devices and insurance."

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies